Media hub

Researchers from the Centenary Institute have found that concealed cardiomyopathy is an important cause of sudden cardiac death where no cause is found from autopsy – and that genetic testing can help identify cases of concealed cardiomyopathy which provides a cause of death and also helps guide care of surviving relatives.

Researchers from the Centenary Institute and the University of Sydney have developed a new nasal vaccination strategy that induces potent lung immunity and protection against the SARS-CoV-2 coronavirus.

Genetic testing can diagnose cardiomyopathy – a disease of the heart muscle – in children and help detect who will have heart failure and require a transplant, a new study has found.

Centenary Institute researchers in the Agnes Ginges Centre for Molecular Cardiology have secured $2.7 million in funding for nationally significant research into cardiovascular disease and sudden cardiac death.

The Centenary Institute and the University of Sydney, together with collaborators, have been awarded an AU$19 million contract from the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health (NIH), to develop the next generation of tuberculosis (TB) vaccines.

Researchers at the Centenary Institute and the University of Technology Sydney have identified a new drug target for the treatment and prevention of chronic obstructive pulmonary disease (COPD), an inflammatory lung disease that causes airway blockage and that makes it difficult to breathe.

The Centenary Institute welcomes the NSW Government’s commitment to fund a new biomedical complex in Camperdown. The Chair of the Centenary Institute Board, Joseph Carrozzi AM, and its Executive Director, Professor Mathew Vadas AO, are thrilled that a biomedical complex, the Sydney Biomedical Accelerator (SBA), will now be a reality.

Researchers from the Centenary Institute and the University of Technology Sydney have published the first study showing why people with chronic obstructive pulmonary disease (COPD) are at higher risk of developing severe COVID-19.

Centenary Institute research has revealed new insight into tackling mycobacterial infections which are responsible for chronic diseases that include tuberculosis (TB), leprosy and serious skin ulcerations.

Dr Annalicia Vaughan from the Centenary UTS Centre for Inflammation is the successful recipient of the Kenyon Foundation Inflammation Award for 2022. The Award, valued at $20,000, will support Dr Vaughan’s study into identifying new microbial-derived biomarkers for the early diagnosis and treatment of lung cancer. The leading cause of cancer death, lung cancer is ...

Centenary Institute researchers have uncovered new insight into Mycobacterium abscessus, a highly drug-resistant bacteria that can cause serious infection and lung damage in vulnerable people. The bacteria is considered an emerging health threat with infection numbers on the rise globally. Commonly found in soil, dust and water, Mycobacterium abscessus is closely related to the bacteria ...

Research led by the Centenary Institute and the Harvard Medical School, Boston, shows that a compound present in current beta blocker treatments could be repurposed to increase efficiency and safety of infantile hemangioma therapies.